population worldwide, and almost two million people in the United States alone. [1] [2] [3] Treatment of epilepsy often imposes an exposure to various anti-epileptic medications (AEDs) and requires long-term commitment and compliance from the patient. 4, 5 Excluding the small percentage of people who underwent successful epilepsy surgery, the vast majority of patients are maintained through chronic medical management for appropriate seizure control. 6, 7 With the advent of the newer generation of AEDs starting in the early 1990s, eight new agents for the treatment of epilepsy have been introduced in the U.S. market. [8] [9] [10] Although these new AEDs provided more treatment selection and underwent FDA-approvals based on randomized double-blind studies, it is often unclear as to which AED should be used for each particular patient. 10, 11 For most patients, it is a process of trial and error with different medications, and at times, their combinations. 10, 12 Minimizing exposures to ineffective or ill-tolerated AEDs to patients would improve perceived quality-of-life and their productivity. 13, 14 Thus, in the process of selecting AEDs, patients' own preference and input play an important role. Commonly, a particular AED is chosen based on seizure types, drug-to drug interactions, metabolism, dosing convenience, comorbidities, and side effect profile. 12, 13, [15] [16] [17] [18] Even though older AEDs (phenytoin, carbamazepine, valproic acid, phenobarbital, primidone, and ethosuximide) have an advantage of lower cost, wide availability, and long-term experience, new AEDs are frequently preferred by neurologists and patients. 10, 12, 17, 19, 20 Recent treatment guidelines by French et al. provide a useful summary for the treatment of new onset and refractory epilepsy. 8, 9, 21, 22 These guidelines are based on class I and class II studies from 1,462 articles, and assess information on efficacy, tolerability, and safety of seven new AEDs. However, in an actual clinical setting, comparison of their efficacy or side effects (SE) alone does not adequately address the main question--will a patient stay on a drug through the years?
We sought to comprehensively evaluate the retention rates of commonly used new AEDs in order to gain information on how they differ in their treatment duration, efficacy, and SE in a clinical setting.
Methods

Data collection and source population
Retention data on commonly used newer AEDs were obtained retrospectively by searching established electronic medical records in our epilepsy center and interviewing patients as needed. To identify patient exposures to new AEDs, over 2000 patient records were reviewed and analyzed. In order to evaluate long-term retention and tolerability, only the patients who either discontinued their newer AEDs within 2 years or continued them 2 years or longer were included. Of these patient records, 828 exposures to the following new AEDs were identified from 479 patients: lamotrigine (LTG), levetiracetam (LEV), oxcarbazepine (OXC), topiramate (TPM), and zonisamide (ZNS). Fewer than 20 epilepsy patients were identified as being treated with the remaining new AEDs, such as felbamate (FBM), neurontin (GBP), tiagabine (TGB), or vigabatrin (VGT). Thus, these AEDs were excluded from our data analysis. The data collected included patient's age, gender, seizure type, current and previous AED use, dosage, main reason for discontinuation, and duration of therapy. Both medical paper charts as well as electronic records were utilized to avoid as much recall bias as possible and ensure collected data were credible and accurate.
Data analysis
Duration of AED therapy was calculated in weeks from the start date of that particular AED. Dosage of medication was recorded in maximum daily doses based on what patient is currently taking or what dosage patient was discontinued on. Continuation of therapy was defined for patients currently treated with same AED since the start of therapy. Discontinuation of therapy was defined for patients who stopped treatment at any given time and main reasons for discontinuation were recorded based on patients' complaints whether they were due to side effects, inefficacy, or other reasons (Table 4) . Side effects were grouped into categories such as behavioral, fatigue, GI, ineffective, rash, kidney stone, hyponatremia, word finding difficulty and others. Once all data was entered in Excel, SAS version 2.1.40 was utilized for further analysis. Survival assessment was made with parametric analysis by Kaplan-Meier method as well as nonparametric, multivariate analyses using the Cox regression analysis. 23, 24 Within the Cox model, possible explanatory variables potentially modifying the outcome of retention rate such as gender, age, or number exposure to other new AEDs were included and examined for their significance of effect. In SAS, this was performed through the use of Proc Phreg. 25, 26 This form of analysis was also able to account for possible effects on retention rate via concurrent AED usage.
Results
Exposure to new AEDs Table 1 summarizes the characteristics of the AED exposures. Of the total 828 data points, there was a slight predominance with female patient exposures (61%). Further logistic regression modeling of duration of medication use did not demonstrate gender as a significant explanatory variable. The mean age of exposure was 38.5 years (17-89). Partial onset seizures were more frequently represented in the data set (80%), as expected from previous epidemiological studies. Of the total 479 patients, 408 (85.1%) were continuing to take at least one of the five new AEDs, while 71 (14.9%) were no longer on any of them. Among them, 48.2% had been exposed to only one of the study AEDs, with 30.9% exposed to two and 13.6% to three of them. The smallest minorities of 4.8% and 2.5% had exposures to four and to all five study medications, respectively.
AED use and duration
Overall, the largest number of AED exposure history was collected from LTG, representing 30.3% of the data, although LEV data followed closely at 23.7%. TPM and ZNS data were similar in quantity at 18.8% and 15.5%, respectively, and the least amount of data was obtained from OXC exposures at 11.7% (Table 2) . This is probably due to the fact that OXC was almost exclusively used for partial onset seizures, while others were used for both partial and generalized onset seizures.
Further stratification of data at different duration points is shown in Table 3 . The cumulative numbers of discontinued exposures were calculated at 4, 12, 24, 52, and 104 weeks. After normalizing the values by the total number of exposure cases for each AED, the resulting percentages showed the most rapid rate of change (i.e. discontinuations) occurring in the first 24 weeks (Fig. 2) . LTG demonstrated the highest retention rate at 4, 12, 24, 52, and 104 weeks, while the lowest retention was seen with LEV at 4 and 12 weeks, and with TPM at 24, 52, and 104 weeks. Although OXC and ZNS percentages were between those of LTG and TPM, overlap was evident among these AEDs at different time points. For example, interval retention rate was higher with OXC at 12 and 24 weeks compare to ZNS, but lower rate was seen later at 104 weeks.
Greater than 80% of patients discontinued AEDs within 24 weeks if they were discontinued, regardless of type of AEDs. For ZNS, more patients tended to discontinue it early (86% of ZNS discontinued group), but once passed the 24 weeks mark, majority of them 298 S. Chung et al. Continued drug use and number of prior drug trials
In Table 4 , the instances of continued medication use were grouped according to the number of prior study AED trials. In addition to these study AEDs, the majority of the patients had tried 1 or 2 older AEDs in the past. The majority of continued medication use had no or one prior trial of the other four study AEDs, the percentages ranging from 71.2% for OXC to 89.7% of retained LTG use. Progressively less continued medication use was seen with more than one drug trial history. For those who had already tried two study AEDs previously, the percentages ranged from 6.9% for LTG to 15.7% for ZNS. For 3 or 4 drug trials, much lower percentages were seen, from 0 to 9.6%.
Reasons for AED discontinuation
As shown in Table 5 , with the exception of LEV, drug ineffectiveness was the primary reason for stopping a particular medication; these percentages ranged from 23.4% of LEV to the maximum at 45.2% of OXC. In the case of LEV, behavioral side effects accounted for 40.4% of discontinued cases. Behavioral side effects included various symptoms including emotional liability, anger outburst, irritability, insomnia, and mood swings. This outnumbered the 23.4% of ineffective cases in this particular AED, which was the lowest percentage for any of the five AEDs.
Comparative retention rates and long-term tolerability of new antiepileptic drugs 299 Sedation or fatigue was also high at 24.5% of the reasons for discontinuing LEV. LTG was stopped for concern of rashes in 26.9% of discontinued cases, the highest among the AEDs; no reports of Steven-Johnson's reaction were found among these cases. Behavioral side effects and sedation/fatigue each resulted in 11.9% cases of LTG discontinuation.
Rash concern was also high in the OXC discontinuations, accounting for 14.3% of cases, the second highest after LTG. OXC also had one unique side effect of hyponatremia, which accounted for 7.1% of OXC discontinuation causes. Compared with other AED, OXC had the lowest percentage of behavioral (4.8%) or sedative side effects (7.1%).
AED discontinuation due to sedating side effect was the highest with TPM exposure group, which accounted for 27.3% of TPM discontinuation causes. Word-finding difficulty was not an infrequent cause to stop TPM at 6.8%, which was the highest among these AEDs. Nephrolithiasis was a minor reason to discontinue TPM accounted for 3.4% and overall incidence of 1.9% to all TPM exposure group.
Sedation/fatigue was a common reason to stop ZNS at 23.5%. ZNS had the highest percentage of gastrointestinal side effects (9.8%) as a reason to discontinue AEDs. On the other hand, behavioral side effect was not frequently reported as a cause to stop ZNS.
The category of 'other' included such varied complaints as paresthesias, allodynia, or indescribable sensations, and monetary cost of medications.
The highest percentage was seen in the TPM population at 18.2% (mainly paresthesias), accounting for a large numbers of TPM cessation cases.
Dosage evaluation
Comparison of mean doses between continuing group and discontinued group for each AED is shown in Table 6 . For each of the five AEDs, t-test of the dosages demonstrated significant differences between the continuing and discontinued groups for LEV ( p = 0.0023), LTG ( p = 0.0006), and ZNS ( p = 0.014). For these AEDs, the mean dosages were higher in the continuing group than the discontinued group. The mean doses for TPM and OXC groups did not show significance ( p = 0.5829 and 0.2024, respectively). There were no significant differences in mean dosages between continuing group and discontinued group due to inefficacy.
Discussion
Our goal was to provide neurologists with helpful information in selecting a long-term treatment among new AEDs. Many factors influence treatment selection including seizure type, gender, age, concurrent AEDs and other co-medications. [27] [28] [29] Successful treatment should consist of finding the balance between obtaining adequate seizure control and avoiding SE, as well as factoring in patient's preference, 19, 30 which can be assessed by AED 300 S. Chung et al. retention rate. Retention rate measures all possible reasons for medication termination including ineffectiveness and intolerability. In other words, retention rate may provide a useful ''feedback'' on treatment plans according to patient's perspective. This provides practical and useful information to optimize the pretrial probability that a particular AED would be successful for the patient. Therefore, while evidence based information and wider selection of AEDs empower neurologists to choose treatments, long-term retention rates could provide useful insights into overall efficacy and tolerability. 19, [30] [31] [32] [33] In addition, retention rate also captures each individual patient's preference and allows patients to decide which side effects are tolerable for them.
There are several caveats when interpret our retention related SE data. First of all, we reported only the severe adverse effects those lead to discontinuation of AEDs, and thus, they are quite different from previously reported SE rates. 30, [34] [35] [36] For example, less severe side effects such as headache or mild nausea played small parts in our study but well-known to be very common in other trials. 30, [37] [38] [39] [40] In other words, even though common, patients did not perceive them severe enough to discontinue their AEDs.
In addition, SE rates quoted in our study are percentage of why that specific AED was discontinued and do not represent overall incidence. For instance, while nephrolithiasis accounted for nearly 6% of reason to discontinue ZNS, overall incidence of nephrolithiasis was less than 2% in all ZNS exposure group. Furthermore, higher retention rate does not necessarily indicate better efficacy. Not everyone in our study was seizure-free and many of them continued to take their AEDs even when they are not completely efficacious. In this regard, retention rate may reflect more of AED tolerability rather than its efficacy. Thus, one should be very cautious before drawing a conclusion that LTG or ZNS is more effective than LEV or TPM based on our study. What our study shows is that LTG was best tolerated among the studied AEDs with subjective efficacy against seizures. Furthermore, the order of these AEDs used had a significant impact on their retention rates. Previous studies have shown that the efficacy of AEDs decreases after the 2nd or 3rd AED had failed. 6, 18, 27 Therefore, a drug used after 2 or 3 prior drug trials may be less likely to be continued (due to inefficacy) as compared to one that was tried at an earlier time point. A potential bias affecting our reported retention rate results would be if one of the medications was systematically used first. Although our database was limited to usage of the five study medications, the consistent trend across each retained medication was that it was most likely to have been preceded by less than two prior drug trials (Table 4 ) with large decreases in retention rate after two or more AED trials. Therefore, within the confines of the retrospective data available, there does not appear to be a bias due to a difference in prior drug use. This could be more concisely addressed by a long-term prospective study with newly treated epilepsy cases that would also account for all AED use.
It is important to point out that when AEDs were discontinued, most of patients did within 6 months regardless of their seizure types or gender ( Table 2 ). This may indicate that effectiveness and tolerability should be thoroughly evaluated at around 6 months after initiating AEDs, and prepare patients for a likely long-term treatment. This study also shows that after initial hurdle of 6 months, continuation rate of all AEDs were notably high and exceeded 90% especially with LTG and ZNS.
There are previously reported retention rates of new and old AEDs (often comparing old versus new). 37, [41] [42] [43] [44] However, due to differences in study designs, prior metanalysis have drawn limited conclusions in the indirect comparison of one medication versus another. 34, 45, 46 Direct comparison studies have been restricted in number of AEDs, typically comparing two or three AEDs simultaneously. 34, [46] [47] [48] [49] In one retrospective cohort study of LTG, TPM, gabapentin, and vigabitrine, investigators determined LTG had the longest time to discontinuation, TPM the shortest. 45 However, final percentage of patients taking LTG and TPM were similar, at 60% and 50% respectively. Another study compared tolerability among five AEDs (TPM, TGB, VGT, GBP, and LTG), and concluded TPM was the most common drug to be withdrawn due to SE. 50 Another similar retrospective cohort study was performed with GBP, LTG, and TPM. 51 The study concluded that TPM and LTG had similar retention rates, although TPM appeared to be more efficacious but with more side effects. Although a number of retention studies have been reported for a single AED, 44, [52] [53] [54] [55] [56] [57] no comparison studies have included OXC, ZNS, or LEV. This study was therefore undertaken to directly compare retention rates in the five commonly used new AEDs in a single epilepsy clinic, examining the rate of discontinuation, dosing, and the reasons for stopping.
We evaluated retention rates both in short-term at 1, 3, and 6 months as well as long-term at 1 and 2 years for all five AEDs. Overall, LTG had the highest retention rate in the short-and the long-term in our study, while TPM had the lowest in the long-term (Figs. 1 and 2 ). Beside LTG, there was no significant difference in the short-term retention rates among the remaining four AEDs. LTG had the highest continuation rate after 6 months of therapy, which distinguished it from the rest with a 2-year-retention rate of 74.1% (Fig. 2) . Even though TPM retention rate was the lowest among five AEDs at 2 years, it was very similar to previously reported rates of 45-50%. 44, 45 Many people complained of sedation and paresthesia, which combined to be about 45% of the causes to discontinue TPM. We also found that significantly more people stopped TPM after 6 months into a therapy than any other AEDs. This may explain why TPM retention rate was low in our long-term study compare to pervious short-term studies. 58, 59 In addition, we also noted that after 6 months, the most common reason to stop TPM was paresthesia and the other non-specific sensory symptoms which might have become increasingly intolerable for patients over time.
In terms of dosages, most of our patients took medium-average daily doses, perhaps exception of ZNS (Table 6 ). Typical dosage for ZNS was ranges between 200 and 500 mg in the literature even though efficacy shown even at 100 mg. 38, [60] [61] [62] [63] [64] It is possible that lower ZNS dosage might have caused higher retention rate in our study by artificially improving tolerability. However, many of our patients continued for a long period of time without increasing to higher dosage, which may indicate adequate efficacy at that low dosage. It was also found that ZNS was utilized for both partial and generalized onset seizures (68% and 32%, respectively) at a similar daily dose.
Beside the comparison of retention rates, several findings were noteworthy in our study. First, retention rates were lower than some of the previous studies especially with OXC, 65 LEV, 52 and TPM. 54 This may due to the fact that our study population has several different baseline characteristics compare to those reported from clinical trials, such as seizure type, degree of intractability, concurrent use of specific AEDs, and the length of follow-up. In addition, more refractory epilepsy population in our clinic may also have contributed to overall low retention rate compare to the other published studies where less severe epilepsy patients were treated. In fact, it was not a surprise to find out that the lack of efficacy was the one of the commonest reason to stop a particular AED. Second, retention rates were not significantly different in patients who were taking AEDs as monotherapy compare to adjunctive therapy. Furthermore, the order of which AED was used first among these AEDs did not make a significant impact on retention rate. This may again due to refractory patient population in our clinic and the fact that these AEDs were commonly used as the third, forth, or fifth choice. And the third, some of the expected AED-specific adverse events were identified but at somewhat different rates than previously reported. For example, approximately 20% of patients reported behavioral or irritability after LEV therapy which was significantly higher than the previously reported incidence. 41, 66 In fact, this was the leading cause of discontinuation for LEV (38%). We did not review their previous psychiatric history and it is not clear whether this could have been a contributing factor. However, we typically do not initiate LEV for anyone who has or had significant psychiatric conditions.
On the other hand, the incidence of rash from LTG in our study (7%) was lower than the previously reported rate of 10%. Everyone except one person in our clinic discontinued LTG once benign rash developed. Exception was a 63-year-old woman who was switched from phenytoin for partial onset seizures. Even though she developed a rash on arms and chest, she decided to continue LTG against our advice, since she felt much better cognitively with LTG. She was briefly treated with oral prednisone and rash disappeared completely within several days. Rash was one of the main causes for discontinuing OXC as well (14.3%), but only one person from LEV group discontinued due to rash. Incidence of symptomatic kidney stone was also somewhat 302 S. Chung et al. Figure 2 Cumulative medication discontinuation by percentages over two years. Discontinued exposures were calculated at 4, 12, 24, 52, and 104 weeks. The highest discontinuation rate was seen within 24 weeks for all AEDs (Greater than 80% of patients discontinued AEDs within 24 weeks). LTG demonstrated the lowest discontinuation rate (or highest retention rate) at 4, 12, 24, 52, andhigher than that of reported for both TPM and ZNS at 1.9% and 2.3%, respectively. There were several limitations of our study besides the aforementioned ''caveats.'' These include absence of information on concurrent older AEDs and the detailed information how each medication was selected prior to initiation. Even though we tried to minimize recall bias as much as possible, accuracy of the information could have been still compromised since it was mainly based on retrospective review. The findings are also based on the limited population in our epilepsy center, which may not represent other epilepsy or general neurology clinics. Thus, a prospective multi-center study is needed to further validate the findings of this study. This study does not contain efficacy information and our retention rates should not be interpreted as efficacy data. For example, one can continue to take medication despite of its lack of efficacy for various reasons. These may include consideration of drug-to-drug interaction, lack of better choice, financial limitation, fear of switching medications, and other emotional or social circumstances. Thus, although higher retention rate may indicate better tolerance and efficacy overall, treatment should be tailored to each individual patient. It would be also useful to obtain a similar retention rate comparison on pediatric patients to see if the retention rates are far different from adult population.
Conclusion
We believe that comparing retention rates of newer AEDs provides useful and practical information in choosing AEDs. Our study showed the highest retention rate at 2 years with LTG and lowest with TPM ( p < 0.001). Beside ineffectiveness, the leading causes of discontinuation of AEDs were irritability or other behavioral effects for LEV, rash for LTG and OXC, as well as sedation for TPM and ZNS. We also found that once these AEDs were tolerated for 6 months, they were highly likely to be continued for two years or longer.
